![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » FDA Says COVID-19 Treatment Remdesivir Shouldn’t Be Compounded
FDA Says COVID-19 Treatment Remdesivir Shouldn’t Be Compounded
![Remdesivir - drug](https://www.fdanews.com/ext/resources/test/Drug-Images4/Remdesivir-drug.gif?t=1594407914&width=430)
February 11, 2021
Gilead Sciences’ FDA-approved antiviral treatment for COVID-19, Veklury (remdesivir), should not be compounded, the FDA has warned.
The agency said it has recently learned that “various entities” are offering to sell the active pharmaceutical ingredient in remdesivir to compounders and that the products could be “substandard or counterfeit.”
And even if they are not, compounders might find it hard to produce a final product that is sufficiently soluble and stable and has the right pH, the agency said.
Upcoming Events
-
21Oct